Targeting RAS–ERK signalling in cancer: promises and challenges
The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumours, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes. Recently, the use of compounds targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clinical outcome in metastatic melanoma and has shown promising clinical activity in additional tumour types. However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance. Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently associated with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The activity of single agent therapies targeting individual RAS effector pathways is limited”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“combinations of inhibitors targeting multiple effector and/or feedback pathways have shown impressive activity in KRAS mutant model systems”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Samatar and Poulikakos, 2014
In the citing paper
“Determinants of primary resistance are not the same in different tumor types that up-regulate various RTKs or their ligands in response to pathway inhibition (111-113).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [113]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Cited by
Items 501–600 of 1,000
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
Bièche, I., Coussy, F., Botty, R. E., Vacher, S., Château‐Joubert, S., Dahmani, A., Montaudon, É., Réyès, C., Gentien, D., Reyal, F., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01158-3 · Cited by 19
Deng, Y., Yu, C., Chen, L., Zhang, X., Lei, Q., Liu, Q., Cai, G., & Liu, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.858901 · Cited by 20
Peng, Z., Gillissen, B. F., Richter, A., Sinnberg, T. W., Schlaak, M. S., & Eberle, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054961 · Cited by 21
Chen, D., Wirth, K. M., Kizy, S., Muretta, J. M., Markowski, T. W., Yong, P., Sheka, A. C., Abdelwahab, H., Hertzel, A. V., Ikramuddin, S., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0763 · Cited by 19
Geerlinks, A. V., & Abla, O. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00569-8 · Cited by 20
Protomer selectivity of type II RAF inhibitors within the RAS/RAF complex
Vasta, J. D., Michaud, A., Zimprich, C., Beck, M., Swiatnicki, M., Zegzouti, H., Thomas, M. R., Wilkinson, J., Crapster, J. A., & Robers, M. B. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.019 · Cited by 18
Wu, D., Yang, S., Yuan, C., Zhang, K., Tan, J., Guan, K., Zeng, H., & Huang, C. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136828 · Cited by 26
Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
Du, M. Y., Zhang, L., Scorsone, K. A., Woodfield, S. E., & Zage, P. E. (2016) · Scientific Reports · doi:10.1038/srep27458 · Cited by 19
IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer
Sakahara, M., Okamoto, T., Oyanagi, J., Takano, H., Natsume, Y., Yamanaka, H., Kusama, D., Fusejima, M., Tanaka, N., Mori, S., et al. (2019) · Cancer Science · doi:10.1111/cas.13964 · Cited by 20
Xi, D., Niu, Y., Li, H., Noha, S. M., Temml, V., Schuster, D., Wang, C., Xu, F., & Xu, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.027 · Cited by 19
A patent review of RAF kinase inhibitors (2010–2018)
Man, R., Zhang, Y., Jiang, A.-Q., & Zhu, H. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1651842 · Cited by 20
Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
Tokumaru, Y., Takabe, K., Yoshida, K., & Akao, Y. (2020) · Cancer Science · doi:10.1111/cas.14357 · Cited by 18
Wang, Y., Yang, S., Zhang, S., & Wu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s245696 · Cited by 20
Targeting protein self-association in drug design
Thabault, L., Liberelle, M., & Frédérick, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.028 · Cited by 19
Tarasov, V. V., Chubarev, V. N., Ashraf, G. M., Dostdar, S. A., Sokolov, A. V., Melnikova, T. I., Sologova, S. S., Grigorevskikh, E., Makhmutovа, A., Kinzirsky, A. S., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190305130141 · Cited by 23
ERK-dependent suicide gene therapy for selective targeting of RTK/RAS-driven cancers
Day, E. K., Campbell, A., Pandolf, A., Rogerson, T., Zhong, Q., Xiao, A., Purow, B. W., & Lazzara, M. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.019 · Cited by 17
Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 19
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Wichmann, J., Rynn, C., Friess, T., Petrig-Schaffland, J., Kornacker, M., Handl, C., Emmenegger, J., Eckmann, J., Herting, F., Frances, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2761 · Cited by 18
Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 19
Gasdermin E regulates the stability and activation of EGFR in human non-small cell lung cancer cells
Xu, L., Shi, F., Wu, Y., Yao, S., Wang, Y., Jiang, X., Su, L., & Liu, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01083-7 · Cited by 18
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 21
Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells
Shi, Y., Huang, X., Chen, G.-B., Wang, Y., Zhi, Q., Liu, Y., Wu, X., Wang, L., Yang, B., Xiao, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10338 · Cited by 18
Perspective on the dynamics of cancer
Derbal, Y. (2017) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-017-0066-5 · Cited by 21
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells
Zhang, Y., Zhang, X., Miao, X., Yuan, Y.-Y., Gao, J., Li, X., Liu, Y., & Tan, P. (2019) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2019.1585820 · Cited by 18
Cao, N., Lu, Y., Liu, J., Cai, F., Xu, H., Chen, J., Zhang, X., Hua, Z.-C., & Zhuang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01094 · Cited by 19
Khawaja, H. A., Campbell, A. D., Roberts, J. Z., Javadi, A., O’Reilly, P. G., McArt, D. G., Allen, W. L., Majkut, J., Rehm, M., Bardelli, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03131-3 · Cited by 18
miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms
Sewastianik, T., Straubhaar, J., Zhao, J., Samur, M., Adler, K., Tanton, H., Shanmugam, V., Nadeem, O., Dennis, P. S., Pillai, V., et al. (2021) · Blood · doi:10.1182/blood.2020009088 · Cited by 21
Epidermal RAF prevents allergic skin disease
Raguz, J., Jerić, I., Niault, T., Nowacka, J. D., Kužet, S.-E., Rupp, C., Fischer, I., Biggi, S., Borsello, T., & Baccarini, M. (2016) · eLife · doi:10.7554/elife.14012 · Cited by 21
Gene heterogeneity in metastasis of colorectal cancer to the lung
Hou, J., Zhang, Y., & Zhu, Z. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.034 · Cited by 19
KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 22
Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Barbon, C., Margonis, G. A., Andreatos, N., Rezaee, N., Sasaki, K., Buettner, S., Damaskos, C., Pawlik, T. M., He, J. P., Wolfgang, C. L., et al. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3766-1 · Cited by 19
Cruz, F. S. D., Diolaiti, D., Turk, A. T., Rainey, A. R., Ambesi‐Impiombato, A., Andrews, S. J., MANSUKHANI, M. M., Nagy, P. L., Alvarez, M. J., Califano, A., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0366-0 · Cited by 17
RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer
Lyu, G., Su, P., Hao, X., Chen, S., Ren, S., Zhao, Z., Gong, Y., Liu, Q., & Shao, C. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0105 · Cited by 17
Guo, J., Ke, S., Chen, Q., Zhou, J., Guo, J., & Qiu, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411584 · Cited by 17
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Shang, Y., Fu, S., Hao, Q., Ying, H., Wang, J., & Shen, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107092 · Cited by 18
He, Q., Li, J., Tao, C., Zeng, C., Liu, C., Zheng, Z., Mou, S., Liu, W., Zhang, B., Yu, X., et al. (2024) · MedComm · doi:10.1002/mco2.525 · Cited by 19
Thamkachy, R., Kumar, R., Rajasekharan, K. N., & Sengupta, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0505-7 · Cited by 18
Müller, E., Bauer, S., Stühmer, T., Mottok, A., Scholz, C. J., Steinbrunn, T., Brünnert, D., Brandl, A., Schraud, H., Kressmann, S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.264 · Cited by 18
Wang, H., Liu, S., Kong, F., Xiao, F., Li, Y., Wang, H., Zhang, S., Huang, D., Wang, L., & Yang, Y. (2020) · Oncology Reports · doi:10.3892/or.2020.7586 · Cited by 25
The Role of the Hedgehog Pathway in Cholangiocarcinoma
Anichini, G., Carrassa, L., Stecca, B. A., Marra, F., & Raggi, C. (2021) · Cancers · doi:10.3390/cancers13194774 · Cited by 17
Morante, M., Pandiella, A., Crespo, P., & Herrero, A. (2022) · Biomolecules · doi:10.3390/biom12111562 · Cited by 23
Jamieson, D., Griffin, M. J., Sludden, J., Drew, Y., Cresti, N., Swales, K. E., Merriman, M., Allen, R. A., Bevan, P., Buerkle, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.026 · Cited by 19
ERF deletion rescues RAS deficiency in mouse embryonic stem cells
Mayor‐Ruiz, C., Olbrich, T., Drosten, M., Lecona, E., Vega-Sendino, M., Ortega, S., Domínguez, O., Barbacid, M., Ruiz, S., & Fernández-Capetillo, Ó. (2018) · Genes & Development · doi:10.1101/gad.310086.117 · Cited by 17
Chen, W., Zhang, W., Chen, M., Yang, C., Fang, T., Wang, H., Reid, L. M., & He, Z. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00714-4 · Cited by 17
Al-Wahaibi, L. H., Mohammed, A. F., Abdelrahman, M. H., Trembleau, L., & Youssif, B. G. M. (2023) · Pharmaceuticals · doi:10.3390/ph16071039 · Cited by 18
Chen, Z., Zhang, L., Yang, Y., Liu, H., Kang, X., Nie, Y., & Fan, D. (2023) · Epigenetics · doi:10.1080/15592294.2023.2254976 · Cited by 18
Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
Miao, J., Bai, Y., Miao, Y., Qu, Z., Dong, J., Zhang, R., Aggarwal, D., Jassim, B. A., Nguyen, Q. D., & Zhang, Z. (2023) · Molecules · doi:10.3390/molecules28196947 · Cited by 17
Xie, Y., Sang, Q., Da, Q., Niu, G., Deng, S., Feng, H., Chen, Y., Li, Y., Liu, B., Yang, Y., et al. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102871 · Cited by 18
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 17
Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis
Zu, L., Peng, X., Zeng, Z. R., Wang, J., Meng, L., Shen, W., Hu, C.-T., Yang, Y., & Fu, G. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0782-7 · Cited by 16
Development of Highly Sensitive Biosensors of RAF Dimerization in Cells
Miyamoto, K., & Sawa, M. (2019) · Scientific Reports · doi:10.1038/s41598-018-37213-2 · Cited by 14
Xie, Y., Dong, C. D., Wu, Q., Jiang, Y., Yao, K., Zhang, J., Zhao, S., Ren, Y., Yuan, Q., Chen, X., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23144 · Cited by 16
KinCon: Cell‐based recording of full‐length kinase conformations
Enzler, F., Tschaikner, P., Schneider, R., & Stefan, E. (2020) · IUBMB Life · doi:10.1002/iub.2241 · Cited by 17
Sriskandarajah, P., Brandon, A. D. H., Macleod, K., Carragher, N. O., Kirkin, V., Kaiser, M., & Whittaker, S. R. (2020) · BMC Cancer · doi:10.1186/s12885-020-06735-2 · Cited by 14
Exosome-Contained APOH Associated With Antiphospholipid Syndrome
Tan, Y., Bian, Y., Song, Y., Zhang, Q., & Wan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.604222 · Cited by 17
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients
Rogiers, A., van den Oord, J. J., Garmyn, M., Stas, M., Kenis, C., Wildiers, H. P. M. W., Marine, J., & Wolter, P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0304-7 · Cited by 17
Zou, Y., Liu, F., Wu, J., Wan, L., Fang, S.-F., Zhang, Z., Luo, Y., Chen, M., Huang, M.-Z., He, M., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6435 · Cited by 16
Zhao, M., Wang, D., Che, Y., Wu, M., Li, Q., Shao, C., Wang, Y., Cao, L., Wang, G., & Hao, H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.53 · Cited by 16
Regioselective Synthesis of a C-4′′ Carbamate,C-6′′ n-Pr Substituted Cyclitol Analogue of SL0101
Li, Y., Sandusky, Z. M., Vemula, R., Zhang, Q., Wu, B., Fukuda, S., Li, M., Lannigan, D. A., & O'Doherty, G. A. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c00042 · Cited by 17
Control of Angiogenesis via a VHL/miR-212/132 Axis
Lei, Z., Klasson, T. D., Brandt, M. M., van de Hoek, G., Logister, I., Cheng, C., Doevendans, P. A., Sluijter, J. P. G., & Giles, R. H. (2020) · Cells · doi:10.3390/cells9041017 · Cited by 18
Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
Palušová, V., Renzová, T., Verlande, A., Vaclová, T., Medková, M., Cetlová, L., Sedláčková, M., Hříbková, H., Slaninová, I., Krutá, M., et al. (2020) · Cancers · doi:10.3390/cancers12061516 · Cited by 17
Noormohamadi, H., Samarkhazan, H. S., Kargar, M., Maroufi, F., Servatian, N., & Davami, F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03383-5 · Cited by 17
Bai, Y., Guo, N., Xu, Z., Chen, Y., Zhang, W., Chen, Q., & Bi, Z. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12917 · Cited by 17
Trinder, S. M., McKay, C., Power, P., Topp, M. D., Chan, B., Valvi, S., McCowage, G. B., Govender, D., Kirby, M. L., Ziegler, D. S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154246 · Cited by 18
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 17
Ye, M., Gao, R., Chen, S., Bai, J., Chen, J., Lu, F., Gu, D., Shi, X., Yu, P., Tian, Y., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05092-7 · Cited by 15
Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective
Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608270 · Cited by 14
Messeha, S. S., Zarmouh, N. O., Mendonca, P., Cotton, C., & Soliman, K. F. A. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11240 · Cited by 16
Oxidative and Nitrosative Stress in Oral Squamous Cell Carcinoma
Frohwitter, G., Zimmermann, O. L., Kreutzer, K., Doll, C., Rendenbach, C., Dommisch, H., Wolff, K., Kesting, M. R., Heiland, M., & Koerdt, S. (2020) · Cells Tissues Organs · doi:10.1159/000508705 · Cited by 17
The role of LR-TIMAP/PP1c complex in the occurrence and development of no-reflow
Quan, X., Liu, X., Qin, X., Wang, Y. Z., Sun, T., Li, Z., Zhu, L., Chen, J., Zhou, Y., Singh, S. K., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103251 · Cited by 15
Liu, W., Xie, A., Tu, C., & Liu, W. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0974 · Cited by 15
Novel Treatments in Development for Melanoma
Bernatchez, C., Cooper, Z. A., Wargo, J. A., Hwu, P., & Lizee, G. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_16 · Cited by 15
Das, B., Neilsen, B. K., Fisher, K. W., Gehring, D., Hu, Y., Volle, D. J., Kim, H. S., McCall, J. L., Kelly, D. L., MacMillan, J. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22090-6 · Cited by 18
Cai, R., Huang, M., & Wang, Y. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b03727 · Cited by 15
Erk1/2 inactivation promotes a rapid redistribution of COP1 and degradation of COP1 substrates
Ouyang, W., Guo, P., Takeda, K., Fu, Q., Fang, H., & Frucht, D. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913698117 · Cited by 15
Insight on ecDNA-mediated tumorigenesis and drug resistance
Huang, Q., Zhang, S., Wang, G., & Han, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27733 · Cited by 18
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability
Cantisani, M. C., Parascandolo, A., Perälä, M., Allocca, C., Fey, V., Sahlberg, N., Merolla, F., Basolo, F., Laukkanen, M. O., Kallioniemi, O., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8577 · Cited by 14
Dong, C., Sun, J., Ma, S., & Zhang, G. (2019) · BMC Cancer · doi:10.1186/s12885-019-5750-x · Cited by 14
RetractedZhang, M., Bai, Y., Xu, C., Qi, Y., Meng, J., Zhang, W., Su, H., & Yan, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650846 · Cited by 21
Yang, H., Gao, Y., Xu, D., Xu, K., Liang, S., Zhang, Y., Scherz, A., Hall, S. R. R., Forster, S., Berezowska, S., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01307-2 · Cited by 14
Guo, Z., Xie, Q., Wu, Y., Mo, H., Zhang, J., He, G., Li, Z., Gan, L., Feng, L., Li, T., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00814-9 · Cited by 15
Cheng, M., Cao, H., Yao, P., Guan, J., Wu, P., Ji, H., Jiang, S., Yuan, Y., Fu, L., Zheng, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06069-4 · Cited by 16
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamaría, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 19
Liu, E., Xue, Z., Ye, L., & Liao, Y. (2024) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2024.0274 · Cited by 33
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Wang, J., Zhang, Z.-G., Ding, Z., Dong, W., Liang, H.-F., Chu, L., Zhang, B.-X., & Chen, X. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.04.056 · Cited by 14
An Update on Chemical Classes Targeting ERK1/2 for the Management of Cancer
Pathania, S., & Rawal, R. K. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0339 · Cited by 14
Kim, C., Wang, D., Bokesch, H. R., Fuller, R. W., Smith, E. A., Henrich, C. J., Durrant, D., Morrison, D. K., Bewley, C. A., & Gustafson, K. R. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00136 · Cited by 14
Stein, E. S., Rahal, I. A., Bushi, D., Gera, O., Sharon, R., Gofrit, S. G., Pollak, L., Mindel, E., Maggio, N., Kloog, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103419 · Cited by 16
Campos, L. E., Garibotto, F. M., Angelina, E., Kos, J., Goněc, T., Marvanová, P., Vettorazzi, M., Oravec, M., Jendrzejewska, I., Jampílek, J., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104145 · Cited by 14
Anti-EGFR treatment effects on laryngeal cancer stem cells.
Fernandes, G. M. D. M., Galbiatti, A. L. S., Ferreira, L. A. M., Serafim, V., Rodrigues-Fleming, G. H., de Oliveira-Cucolo, J. G., Biselli-Chicote, P. M., Kawasaki‐Oyama, R. S., Maníglia, J. V., Pavarino, É. C., et al. (2021) · Europe PMC (PubMed Central) · Cited by 14
Huang, H., Liu, Q., Zhang, T., Zhang, J., Zhou, J., Jing, X., Tang, Q., Huang, C., Zhang, Z., Zhao, Y., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s318124 · Cited by 14
Nakagawa, N., Kikuchi, K., Yagyu, S., Miyachi, M., Iehara, T., Tajiri, T., Sakai, T., & Hosoi, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.038 · Cited by 16
An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila
Kushnir, T., Bar-Cohen, S., Mooshayef, N., Lange, R., Bar-Sinai, A., Rozen, H., Salzberg, A., Engelberg, D., & Paroush, Z. (2019) · Genetics · doi:10.1534/genetics.119.302794 · Cited by 13
Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets
Sahoo, S., Singh, P., Kalha, B., Singh, O., & Pal, R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1938-x · Cited by 14
Liu, R., Yin, C., Zhao, P., Guo, B., Ke, W., Zheng, X., Xie, D., Wang, Y., Wang, G., Jia, Y., et al. (2023) · Biology Direct · doi:10.1186/s13062-023-00428-z · Cited by 17
Synergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
Wu, J., Chen, Y., Li, R., Guan, Y., Chen, M. H., Yin, H., Yang, X., Jin, M., Huang, B., Ding, X., et al. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202203005 · Cited by 18
Montenegro, M. F., Martí-Díaz, R., Navarro, A., Tolivia, J., Sánchez‐del‐Campo, L., Cabezas‐Herrera, J., & Rodríguez‐López, J. N. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06288-9 · Cited by 15
Lee, K., Choi, Y., Lim, H.-I., Cho, K.-J., Kang, N., & Ko, S. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04347-y · Cited by 15
Ali, L., Rauf, S., Khan, A. A., Rasool, S., Raza, R. Z., Alshabrmi, F. M., Khan, T., Suleman, M., Waheed, Y., Mohammad, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305417 · Cited by 13
Metadata
- Authors
- Samatar, A. A., & Poulikakos, P. I.
- Affiliations
- Tisch Cancer Institute (US)
- Corresponding author
- Poulikakos, Poulikos I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-12
- Volume
- 13
- Issue
- 12
- Pages
- 928-942
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2050573392
- Cited by
- 1,163
- References
- 139
- Citations by year
- 2026: 47 · 2025: 77 · 2024: 106 · 2023: 100 · 2022: 102 · 2021: 134 · 2020: 119 · 2019: 105 · 2018: 117 · 2017: 101 · 2016: 108 · 2015: 45 · 2014: 2
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- RAF inhibitors, MEK inhibitors, ERK inhibitor, KRAS mutation, NRAS mutation, BRAF mutation, acquired drug resistance, intrinsic drug resistance, metastatic melanoma, targeted cancer therapy, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Delivery Systems, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.